DENTSPLY SIRONA Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. DENTSPLY SIRONA Inc. is the world's largest diversified manufacturer of professional dental products and technologies, operating through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company is a large accelerated filer with shares trading on the Nasdaq under the symbol XRAY.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $936 | $984 | $1,815 | $1,937 |
| Gross Profit | $490 | $511 | $956 | $1,017 |
| Operating Income (Loss) | $(128) | $50 | $(65) | $92 |
| Net Income (Loss) | $(44) | $(4) | $(25) | $13 |
| Diluted EPS | $(0.22) | $(0.02) | $(0.13) | $0.07 |
| Cash from Operations (YTD) | $55 | $233 | $55 | $233 |
| Total Debt (Current + Long-term) | $2,402 | $2,135 | $2,402 | $2,135 |
| Cash and Equivalents | $359 | $279 | $359 | $279 |
Segment Adjusted Operating Income (Q2 2025): Connected Technology Solutions ($12M), Essential Dental Solutions ($151M), Orthodontic and Implant Solutions ($45M), Wellspect Healthcare ($25M). Total segment adjusted operating income was $233M before reconciling items.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4.9% in Q2 and 6.3% YTD compared to 2024. On a constant currency basis, sales declined 6.7% (Q2) and 5.6% (YTD). The decline was driven by lower volumes in the Orthodontic and Implant Solutions segment due to the suspension of Byte sales, as well as lower CAD/CAM and implant volumes.
- Significant Impairments: The company recorded a pre-tax goodwill impairment of $156 million and intangible asset impairments of $79 million (totaling $235 million) in Q2 2025. These charges were primarily driven by the impact of tariffs, lower projected volumes, and competitive pressures in the Implant & Prosthetic Solutions reporting unit and Connected Technology Solutions segment.
- Operating Loss: The company reported an operating loss of $128 million in Q2 2025, compared to operating income of $50 million in Q2 2024, primarily due to the impairment charges.
- Cost Reductions: SG&A expenses decreased 14.5% in Q2 and 14.0% YTD, driven by lower headcount and advertising costs for Byte products, as well as restructuring initiatives.
- Financing Activity: In June 2025, the company issued $550 million of 8.375% Junior Subordinated Notes due 2055. Proceeds were used to repay a $435 million bridge loan and for general corporate purposes.
Guidance, Outlook, Risks, and Unusual Items
- Restructuring Plans: The company is executing a 2024 restructuring plan approved in July 2024, targeting a 2-4% global workforce reduction and $80-$100 million in annual cost savings. As of June 30, 2025, $30 million in charges have been incurred under this plan. A prior 2023 plan is substantially complete.
- Tariff and Geopolitical Risks: Recent U.S. tariff policies (including a baseline 10% tariff and higher rates for specific nations) and geopolitical conflicts (Russia-Ukraine, Middle East) pose risks to supply chains, costs, and demand. The company notes that tariffs have reduced royalty rates used in asset valuations, contributing to impairments.
- Byte Suspension: The suspension of Byte aligner sales significantly impacted the Orthodontic and Implant Solutions segment. The company refined estimates for customer refunds, resulting in favorable adjustments to net sales, but volumes remain lower.
- Future Impairment Risk: Management warns that fair values of certain indefinite-lived intangible assets approximate carrying values. Further declines in key assumptions (e.g., discount rates, revenue projections) could lead to additional material impairments.
- Liquidity: The company maintains $737 million in available borrowings under lines of credit and commercial paper facilities. Management believes sufficient liquidity is available for the next 12 months.
- Legal Proceedings: The company is involved in multiple securities litigations and derivative suits regarding revenue recognition and the Byte acquisition. A $84 million settlement for a 2018 class action was preliminarily approved in January 2025, with a final hearing scheduled for September 2025.
Key Facts for Investor Verification
- Impairment Drivers: Verify the specific impact of tariffs and competitive pressures on the Implant & Prosthetic Solutions reporting unit, which led to the $235 million impairment charge.
- Byte Business Status: Confirm the timeline and strategic rationale for the suspension of Byte sales and the potential for future revenue recovery in the aligner market.
- Debt Covenants: Review the amended debt covenants (senior debt to capitalization ratio not to exceed 0.6) and ensure ongoing compliance given the recent debt issuance and operating losses.
- Working Capital Trends: Monitor the increase in days sales outstanding (59 days vs. 55 days) and days sales in inventory (141 days vs. 124 days), which contributed to lower operating cash flow.
- Legal Exposure: Track the status of the consolidated securities litigations and the final approval of the $84 million settlement, including the net cash impact after insurance recoveries.